Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

   Completed · Phase 3 · Colitis, Ulcerative

   NCT02620046 · Takeda Pharmaceuticals U.S.A., Inc. · 7 U.S. investigators

   $126,521research payments

2. PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717

   Active, not recruiting · Phase 1, Phase 2 · Prion Disease

   NCT06153966 · Ionis Pharmaceuticals, Inc. · 4 U.S. investigators

   $125,260research payments

3. A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

   Active, not recruiting · Phase 3 · Osteoarthritis

   NCT07153471 · Eli Lilly and Company · 22 U.S. investigators

   $124,581research payments

4. A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

   Recruiting · Phase 3 · Immunoglobulin G4 Related Disease

   NCT07190196 · Genzyme Corporation · 5 U.S. investigators

   $124,445research payments

5. A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)

   Completed · Primary Biliary Cholangitis

   NCT07049887 · Ipsen Biopharmaceuticals, Inc · 3 U.S. investigators

   $124,082research payments

6. A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

   Completed · Phase 1 · Advanced Solid Tumors

   NCT03595059 · AbbVie Inc. · 7 U.S. investigators

   $124,060research payments

7. Goal Attainment and Physical Activity in People With Hemophilia A

   Terminated · Hemophilia A

   NCT06530030 · Sanofi US Services Inc. · 9 U.S. investigators

   $123,871research payments

8. A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma

   Terminated · Phase 1, Phase 2 · Lymphoma, Non-Hodgkin

   NCT05255601 · E.r. Squibb & Sons, L.l.c. · 11 U.S. investigators

   $123,572research payments

9. A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

   Active, not recruiting · Phase 2 · Melanoma

   NCT06101134 · E.r. Squibb & Sons, L.l.c. · 6 U.S. investigators

   $122,889research payments

10. Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

    Completed · Phase 3 · Obstructive Sleep Apnea

    NCT05412004 · Eli Lilly and Company · 9 U.S. investigators

    $122,826research payments

11. [Trial of device that is not approved or cleared by the U.S. FDA]

    Withheld

    NCT06724081 · Radiometer America, Inc · 1 U.S. investigator

    $122,637research payments

12. Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

    Active, not recruiting · Phase 2 · Castration-resistant Prostate Cancer

    NCT05502315 · E.r. Squibb & Sons, L.l.c. · 4 U.S. investigators

    $122,635research payments

13. Cold Agglutinin Disease Real World Evidence Registry

    Active, not recruiting · Cold Agglutinin Disease (CAD)

    NCT05791708 · Sanofi US Services Inc. · 19 U.S. investigators

    $122,556research payments

14. Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial

    Recruiting · Not applicable · Prostate Cancer

    NCT06496256 · Teleflex LLC · 4 U.S. investigators

    $121,919research payments

15. A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

    Completed · Phase 4 · Attention Deficit Hyperactivity Disorder

    NCT04085172 · Takeda Pharmaceuticals U.S.A., Inc. · 8 U.S. investigators

    $121,660research payments

16. Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy

    Recruiting · Phase 4 · Allergic Reactions

    NCT06834165 · Ars Pharmaceuticals Operations, Inc. · 2 U.S. investigators

    $121,319research payments

17. Adjustable Continence Therapy (ACT) for the Treatment of Female SUI

    Recruiting · Not applicable · Urinary Incontinence

    NCT04248283 · Uromedica, Incorporated · 4 U.S. investigators

    $121,027research payments

18. A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

    Recruiting · Phase 3 · Bipolar Disorder Type I With Mania

    NCT06929273 · E.r. Squibb & Sons, L.l.c. · 52 U.S. investigators

    $119,798research payments

19. A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

    Recruiting · Phase 1, Phase 2 · Immune Thrombocytopenia (ITP)

    NCT06721013 · Eli Lilly and Company · 7 U.S. investigators

    $119,312research payments

20. A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

    Completed · Phase 3 · Axial Spondyloarthritis

    NCT04436640 · UCB SA · 5 U.S. investigators

    $118,767research payments

21. A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

    Completed · Phase 3 · Obesity

    NCT04847557 · Eli Lilly and Company · 7 U.S. investigators

    $118,055research payments

22. Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus

    Enrolling by invitation · Phase 3 · Lupus Erythematosus, Systemic

    NCT06475742 · Idorsia Pharmaceuticals US Inc · 10 U.S. investigators

    $117,661research payments

23. Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

    Recruiting · Phase 1 · Head and Neck Cancer

    NCT05526924 · Beigene Switzerland GmbH · 1 U.S. investigator

    $117,303research payments

24. A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants.

    Completed · Phase 1 · Rheumatoid Arthritis

    NCT05858788 · Sanofi US Services Inc. · 1 U.S. investigator

    $117,255research payments

25. A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

    Completed · Phase 3 · Crohn's Disease

    NCT03926130 · Eli Lilly and Company · 20 U.S. investigators

    $117,142research payments

26. Misago® RX Self-expanding Peripheral Stent for Common and/or External Iliac Artery

    Completed · Not applicable · Iliac Artery Stenosis

    NCT02793492 · Terumo Medical Corporation · 8 U.S. investigators

    $117,035research payments

27. Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)

    Completed · Phase 3 · Parkinson Disease

    NCT04542499 · AbbVie Inc. · 16 U.S. investigators

    $116,945research payments

28. A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

    Completed · Phase 4 · Hypogonadism

    NCT03518034 · AbbVie Inc. · 9 U.S. investigators

    $116,771research payments

29. Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium Levels

    Recruiting · Phase 2 · Hyperkalemia

    NCT05766839 · Vifor Pharma, Inc. · 7 U.S. investigators

    $116,680research payments

30. A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

    Recruiting · Phase 2, Phase 3 · Generalized Myasthenia Gravis

    NCT06055959 · UCB SA · 6 U.S. investigators

    $116,368research payments

31. A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult Participants for the Change of Their Overall Facial Appearance

    Completed · Phase 4 · Mid Face Volume Deficit

    NCT07186595 · AbbVie Inc. · 10 U.S. investigators

    $115,491research payments

32. A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants

    Completed · Phase 2 · Gram-Negative Bacterial Infections

    NCT06086626 · Shionogi Inc · 2 U.S. investigators

    $115,351research payments

33. A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)

    Active, not recruiting · Phase 1, Phase 2 · Gaucher Disease

    NCT05487599 · Eli Lilly and Company · 3 U.S. investigators

    $115,164research payments

34. REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction

    Terminated · Phase 2 · Heart Failure

    NCT06237309 · Regeneron Pharmaceuticals, Inc. · 2 U.S. investigators

    $114,863research payments

35. A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)

    Active, not recruiting · Crohn's Disease

    NCT02130362 · AbbVie Inc. · 29 U.S. investigators

    $113,955research payments

36. Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

    Recruiting · Phase 1, Phase 2 · Geographic Atrophy

    NCT07160179 · AbbVie Inc. · 4 U.S. investigators

    $113,826research payments

37. An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)

    Completed · Dry Eye

    NCT06439394 · AbbVie Inc. · 1 U.S. investigator

    $113,746research payments

38. Observational, Non-Interventional Study Supporting Validation of eVO2peak Using Results in Patients Receiving Standard of Care Cardiopulmonary Exercise Tests (CPET)

    Recruiting · Cardiopulmonary

    NCT05678530 · Prolaio, Inc. · 3 U.S. investigators

    $113,708research payments

39. Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older

    Terminated · Phase 3 · COVID-19

    NCT04904549 · Sanofi Pasteur Inc. · 19 U.S. investigators

    $112,842research payments

40. Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

    Active, not recruiting · Phase 2 · Non-small Cell Lung Cancer

    NCT03539536 · AbbVie Inc. · 15 U.S. investigators

    $112,755research payments

41. A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)

    Recruiting · Phase 2 · Colo-rectal Cancer

    NCT07058012 · Regeneron Pharmaceuticals, Inc. · 3 U.S. investigators

    $112,627research payments

42. Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects

    Completed · Phase 3 · Plaque Psoriasis

    NCT05172726 · Organon Llc · 10 U.S. investigators

    $112,606research payments

43. Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study

    Active, not recruiting · Phase 2 · Chronic Lymphocytic Leukemia

    NCT05718869 · Beigene USA, Inc. · 1 U.S. investigator

    $112,481research payments

44. An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

    Active, not recruiting · Phase 3 · Myeloproliferative Disorders

    NCT04717414 · E.r. Squibb & Sons, L.l.c. · 7 U.S. investigators

    $112,282research payments

45. Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular Trauma

    Completed · Phase 2, Phase 3 · Trauma

    NCT03005418 · Humacyte Global, Inc. · 12 U.S. investigators

    $111,631research payments

46. A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

    Completed · Plasma Cell Myeloma

    NCT04458831 · Sanofi US Services Inc. · 11 U.S. investigators

    $111,477research payments

47. A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old

    Terminated · Phase 2 · Erosive Esophagitis

    NCT02615184 · Takeda Pharmaceuticals U.S.A., Inc. · 6 U.S. investigators

    $111,299research payments

48. Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

    Recruiting · Phase 3 · Hemophilia B

    NCT07080905 · Csl Behring · 5 U.S. investigators

    $111,182research payments

49. Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy

    Enrolling by invitation · Phase 2 · Neovascular Age-related Macular Degeneration

    NCT03999801 · AbbVie Inc. · 36 U.S. investigators

    $111,076research payments

50. A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

    Recruiting · Phase 2, Phase 3 · Non-Squamous Non-Small Cell Lung Cancer

    NCT07005102 · AbbVie Inc. · 5 U.S. investigators

    $110,715research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.